An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)

Status:
Completed

Trial end date:
2020-03-19

Target enrollment:

Participant gender:

This study is being conducted to compare the relationship of patient response to treatment to changes in tumor environment.

Phase 1

Regeneron Pharmaceuticals

Sanofi

Cemiplimab